A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER3-EXPRESSING ADVANCED BREAST CANCER AND NON–SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM HER3-EXPRESSING ADVANCED SOLID TUMORS (The TUXEDO-3 Study)
This research study, called TUXEDO-3, is testing a new treatment named Patritumab deruxtecan. It's for people with advanced breast cancer or non-small cell lung cancer that has spread to the brain, or for those with certain advanced solid cancers where the cancer has spread to the lining of the brain and spinal cord (leptomeningeal carcinomatosis). The main goal is to see how effectively this new drug shrinks tumors and to understand if it helps people live longer. This is a Phase II study, meaning it's exploring how well the treatment works and ensuring it's safe, after earlier tests have shown promise. Researchers will be carefully monitoring participants to understand the drug's effects.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is investigating a new medication called Patritumab deruxtecan for specific types of advanced cancer. The main focus is on advanced breast cancer and advanced non-small cell lung cancer that has spread to the brain. It also includes people with other advanced solid cancers where the cancer has spread to the delicate membranes protecting the brain and spinal cord, a condition known as leptomeningeal carcinomatosis.
The research aims to find out how effective this new drug is at reducing the size of the tumors, both in the brain and in other parts of the body. For some patients, the study will also look at how many people are still alive three months after starting the treatment. By understanding these effects, doctors hope to gain valuable information about whether Patritumab deruxtecan could be a helpful treatment option for these challenging cancers.
This is a Phase II study, which means it's an important step in developing new treatments. Drugs typically go through several phases of testing. Phase I studies check for safety, and Phase II studies like this one explore how well the treatment works and continue to monitor for side effects. If the results are promising, the drug might move on to larger Phase III studies, where it would be compared to existing treatments.
النقاط الرئيسية
- Tests a new drug called Patritumab deruxtecan.
- Aims to treat advanced breast/lung cancer spread to the brain, or other solid cancers spread to the brain lining.
- Main goals are tumor shrinkage and life expectancy for specific patient groups.
- هذه دراسة من المرحلة الثانية، تستكشف الفعالية والسلامة.
- Participation involves receiving the drug and regular health check-ups.
من قد يكون مؤهلاً؟
لكي يتم اعتبارك للمشاركة في هذه الدراسة، يجب أن تكون قد بلغت 18 عامًا أو أكثر. الدراسة مفتوحة لكل من الرجال والنساء.
Specifically, you would need to have advanced breast cancer or non-small cell lung cancer that has spread to your brain. This spread to the brain should either be new and untreated, or it might be cancer that has grown despite previous treatment. Alternatively, you might be eligible if you have another type of advanced solid cancer that has spread to the lining of your brain and spinal cord.
It's important to remember that these are just a few of the main criteria. Your doctor or the study team will review all your medical information to see if this study is the right fit for you, as there are many other detailed requirements for joining.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Do you have advanced breast cancer that has spread to your brain, or advanced non-small cell lung cancer that has spread to your brain?
- Or, do you have another advanced solid cancer that has spread to the lining of your brain and spinal cord?
- Has your brain cancer either not been treated yet, or has it grown despite previous treatment?
ماذا يتضمن المشاركة؟
If you join this study, you will receive the study drug, Patritumab deruxtecan. You'll have regular hospital visits for treatments, health check-ups, and tests to monitor your progress and look for any side effects. These tests may include scans (like MRI or CT scans) to see how your tumours are responding, and blood tests to check your general health. The exact schedule for visits and tests will be explained in detail by the study team. You will continue to be monitored for a certain period even after you stop receiving the treatment.
المخاطر والفوائد المحتملة
المواقع (2)
- —غير مؤكدالنمسا
- —غير مؤكدإسبانيا
أسئلة شائعة
ما هو الهدف الرئيسي من هذه الدراسة؟
The main purpose is to see how well a new drug, Patritumab deruxtecan, works at shrinking cancer that has spread to the brain or brain lining, and to see if it helps people live longer.
ما نوع السرطان الذي تركز عليه هذه الدراسة؟
It focuses on advanced breast cancer or non-small cell lung cancer that has spread to the brain, or other advanced solid cancers spread to the brain and spinal cord lining.
ماذا يعني دراسة 'المرحلة الثانية'؟
Phase II means researchers are trying to understand how effective the new treatment is and continue to look for side effects, building on safety information from earlier tests.
Will I get a new drug if I join?
Yes, if you join this study, you will receive the experimental drug called Patritumab deruxtecan.
هل يمكنني مغادرة الدراسة إذا غيرت رأيي؟
Yes, very importantly, you can decide to stop participating in the study at any time, for any reason, and your regular medical care will not be affected.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.